ReviewCancer medicine2021
Perspectives and controversies regarding the use of natural products for the treatment of lung cancer.
Review in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 74 citations in OpenAlex.
- Jaceosidin inhibits cell viability and induces apoptosis in non-small cell lung cancer by inhibiting the Ras/Raf/MEK/ERK and Akt pathways.Oncology letters · 2026Article
- Therapeutic Potential and Phytochemical Composition ofScientifica · 2026Article
- Fucoidan for Lung Cancer Therapy: A Review of Classification, Mechanisms, and Preclinical Studies.ACS omega · 2025Review
- Effect of extracellular vesicle ZNF280B derived from lung cancer stem cells on lung cancer progression.Cancer biology & therapy · 2025Article
- Mitochondrial alterations induced by Macrovipera lebetina venom.European biophysics journal : EBJ · 2025Article
- Targeting the Unfolded Protein Response with Natural Products: Therapeutic Potential in ER Stress-Related Diseases.International journal of molecular sciences · 2025Review
- Deciphering the effects of bixin on pulmonary alveolar adenocarcinoma migration and proliferation via targeting BAX/BCL-2 and Cyclin D1.Scientific reports · 2025Article
- EM-12, a natural sesquiterpene lactone extracted from Elephantopus mollis, promotes cancer cell apoptosis by activating ER stress.Medical oncology (Northwood, London, England) · 2025Article
- Harnessing nutrients and natural products for sustainable drug development against aging.Frontiers in pharmacology · 2025Review
- Screening andAnti-cancer agents in medicinal chemistry · 2025Article
- Tick saliva protein fraction inhibits breast cancer by decreasing cell viability and promoting apoptosis in vitro.PloS one · 2025Article
- Natural products as therapeutics for malignant melanoma: preclinical evidence and mechanism.Frontiers in pharmacology · 2025Review
- Traditional Herbal Plants and their Phytoconstituents Based Remedies for Respiratory Diseases: A Review.The open respiratory medicine journal · 2025Review
- EGCG's anticancer potential unveiled: triggering apoptosis in lung cancer cell lines throughPeerJ · 2025Article
- Phytochemical-mediated efferocytosis and autophagy in inflammation control.Cell death discovery · 2024Review
- Bone sialoprotein facilitates anoikis resistance in lung cancer by inhibiting miR-150-5p expression.Journal of cellular and molecular medicine · 2024Article
- β-Elemene induced ferroptosis via TFEB-mediated GPX4 degradation in EGFR wide-type non-small cell lung cancer.Journal of advanced research · 2024Article
- Natural Products as Regulators against Matrix Metalloproteinases for the Treatment of Cancer.Biomedicines · 2024Review
- Natural products targeting autophagy and apoptosis in NSCLC: a novel therapeutic strategy.Frontiers in oncology · 2024Review
- Cucurbitacin E Exerts Anti-Proliferative Activity via Promoting p62-Dependent Apoptosis in Human Non-Small-Cell Lung Cancer A549 Cells.Current issues in molecular biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer-related mortality both in men and women and accounts for 18.4% of all cancer-related deaths. Although advanced therapy methods have been developed, the prognosis of lung cancer patients remains extremely poor. Over the past few decades, clinicians and researchers have found that chemical compounds extracted from natural products may be useful for treating lung cancer. Drug formulations derived from natural compounds, such as paclitaxel, doxorubicin, and camptothecin, have been successfully used as chemotherapeutics for lung cancer. In recent years, hundreds of new natural compounds that can be used to treat lung cancer have been found through basic and sub-clinical research. However, there has not been a corresponding increase in the number of drugs that have been used in a clinical setting. The probable reasons may include low solubility, limited absorption, unfavorable metabolism, and severe side effects. In this review, we present a summary of the natural compounds that have been proven to be effective for the treatment of lung cancer, as well as an understanding of the mechanisms underlying their pharmacological effects. We have also highlighted current controversies and have attempted to provide solutions for the clinical translation of these compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.